Grifols

Plasma-derived therapeutics

GRF · BME · Spain

Public Market Listing

GRFBME

BME primary exchange listing

Live quotes, historical charts, and market capitalization for Grifols are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
fostamatinib(Tavalisse)
Approved
Spleen tyrosine kinase (Syk)Small molecule
Immune Thrombocytopenia
Phase 3
Hepatitis B virus (HBV)Protein / enzyme therapeutic
Indication not yet linked
ABvac40No recent activity
Phase 2
Amyloid-beta (Aβx-40)Vaccine
Alzheimer's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$8.5B$483M$970M—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.8B$416M$1.0B—report ↗
2023-FY$7.1B$428M$586M—report ↗
2022-FY$6.4B$381M$584M—report ↗